Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07994525
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-07994525 is an investigational oral small molecule being developed by Pfizer for the treatment of relapsed or refractory multiple myeloma (R/R MM) and other advanced malignancies. It is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The clinical program includes dose-escalation and dose-expansion phases, as well as assessments of potential drug-drug interactions, such as its effect on CYP3A4 metabolism using midazolam as a probe. While its specific molecular target remains undisclosed, it represents a novel addition to Pfizer's hematology-oncology pipeline.
Beyond the preview
Go deeper on PF-07994525.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07994525.